ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Race, Age Play Role In Delay Of Surgery For Breast Cancer

December 28, 2007

ICF Clement Joins Dynalectron In FCRF

January 9, 1987

FDA Subcommittee Leaning Toward Mouse-Dog Drug Testing New Preclinical Toxicity-Protocol

July 20, 1979

No Interest Seen Yet In Specialized Centers For Environmental Carcinogenesis

September 26, 1975

Race For The Cure Grants For National Capital Area.

June 29, 2001

In Brief: FDA Stops Imports Of Counterfeit Adriamychin; Rosenburg: NIH Pay 25-33% That Of Academia

April 22, 1988